Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ANVS |
---|---|---|
09:32 ET | 6005 | 6.422 |
09:33 ET | 1123 | 6.37 |
09:35 ET | 200 | 6.4032 |
09:37 ET | 250 | 6.4529 |
09:39 ET | 300 | 6.4477 |
09:42 ET | 1400 | 6.495 |
09:46 ET | 1200 | 6.46 |
09:48 ET | 500 | 6.54 |
09:50 ET | 700 | 6.56 |
09:51 ET | 801 | 6.535 |
09:55 ET | 1139 | 6.49 |
09:57 ET | 1000 | 6.4896 |
10:00 ET | 3047 | 6.49 |
10:02 ET | 500 | 6.47 |
10:04 ET | 1910 | 6.46 |
10:09 ET | 250 | 6.41 |
10:11 ET | 200 | 6.46 |
10:13 ET | 1200 | 6.4253 |
10:15 ET | 314 | 6.48 |
10:18 ET | 300 | 6.51 |
10:20 ET | 249 | 6.48 |
10:22 ET | 1915 | 6.54 |
10:26 ET | 100 | 6.515 |
10:27 ET | 3600 | 6.57 |
10:31 ET | 544 | 6.52 |
10:36 ET | 199 | 6.54 |
10:42 ET | 500 | 6.56 |
10:44 ET | 300 | 6.56 |
10:45 ET | 936 | 6.59 |
10:47 ET | 773 | 6.58 |
10:51 ET | 400 | 6.5601 |
10:54 ET | 1898 | 6.61 |
10:56 ET | 250 | 6.59 |
11:00 ET | 100 | 6.599 |
11:14 ET | 100 | 6.56 |
11:16 ET | 200 | 6.63 |
11:18 ET | 100 | 6.61 |
11:21 ET | 100 | 6.61 |
11:27 ET | 900 | 6.635 |
11:30 ET | 728 | 6.6699 |
11:34 ET | 1000 | 6.655 |
11:36 ET | 600 | 6.67 |
11:38 ET | 2990 | 6.62 |
11:43 ET | 1150 | 6.63 |
11:48 ET | 695 | 6.62 |
11:54 ET | 308 | 6.63 |
11:56 ET | 200 | 6.625 |
11:57 ET | 450 | 6.6153 |
11:59 ET | 1937 | 6.616 |
12:01 ET | 300 | 6.64 |
12:06 ET | 964 | 6.61 |
12:08 ET | 200 | 6.6 |
12:10 ET | 1543 | 6.59 |
12:12 ET | 1507 | 6.67 |
12:14 ET | 210 | 6.64 |
12:15 ET | 100 | 6.59 |
12:17 ET | 100 | 6.63 |
12:19 ET | 2400 | 6.6455 |
12:21 ET | 400 | 6.69 |
12:32 ET | 300 | 6.64 |
12:42 ET | 1000 | 6.685 |
12:46 ET | 573 | 6.74 |
12:50 ET | 1071 | 6.73 |
12:53 ET | 1300 | 6.7194 |
12:55 ET | 700 | 6.7399 |
12:57 ET | 6630 | 6.74 |
01:02 ET | 100 | 6.755 |
01:08 ET | 300 | 6.74 |
01:09 ET | 100 | 6.76 |
01:11 ET | 500 | 6.75 |
01:13 ET | 184 | 6.76 |
01:15 ET | 1000 | 6.7584 |
01:20 ET | 1100 | 6.76 |
01:22 ET | 200 | 6.76 |
01:24 ET | 901 | 6.79 |
01:26 ET | 2109 | 6.8298 |
01:27 ET | 4691 | 6.88 |
01:29 ET | 400 | 6.865 |
01:31 ET | 1100 | 6.8714 |
01:33 ET | 1000 | 6.89 |
01:38 ET | 100 | 6.885 |
01:40 ET | 1405 | 6.87 |
01:42 ET | 513 | 6.87 |
01:45 ET | 200 | 6.86 |
01:47 ET | 1088 | 6.84 |
01:49 ET | 440 | 6.83 |
01:51 ET | 300 | 6.8193 |
01:54 ET | 100 | 6.82 |
01:56 ET | 742 | 6.81 |
02:03 ET | 1267 | 6.7917 |
02:09 ET | 447 | 6.77 |
02:12 ET | 613 | 6.77 |
02:14 ET | 350 | 6.77 |
02:25 ET | 500 | 6.78 |
02:32 ET | 272 | 6.78 |
02:34 ET | 500 | 6.78 |
02:41 ET | 1000 | 6.78 |
02:43 ET | 200 | 6.78 |
02:45 ET | 2500 | 6.78 |
02:48 ET | 1157 | 6.79 |
02:50 ET | 702 | 6.79 |
02:52 ET | 300 | 6.77 |
03:01 ET | 1832 | 6.7501 |
03:03 ET | 100 | 6.735 |
03:06 ET | 100 | 6.735 |
03:08 ET | 100 | 6.75 |
03:17 ET | 4100 | 6.7806 |
03:19 ET | 820 | 6.79 |
03:21 ET | 5115 | 6.74 |
03:24 ET | 600 | 6.74 |
03:26 ET | 1600 | 6.76 |
03:28 ET | 100 | 6.775 |
03:30 ET | 100 | 6.775 |
03:32 ET | 264 | 6.76 |
03:35 ET | 300 | 6.745 |
03:42 ET | 900 | 6.765 |
03:44 ET | 100 | 6.765 |
03:46 ET | 215 | 6.78 |
03:48 ET | 508 | 6.76 |
03:51 ET | 1483 | 6.745 |
03:53 ET | 1200 | 6.77 |
03:55 ET | 400 | 6.785 |
03:57 ET | 3357 | 6.82 |
04:00 ET | 14160 | 6.79 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Annovis Bio Inc | 93.7M | -1.8x | --- |
Nuvectis Pharma Inc | 94.7M | -4.2x | --- |
Genenta Science SPA | 87.8M | -9.4x | --- |
Regulus Therapeutics Inc | 91.7M | -1.3x | --- |
Cabaletta Bio Inc | 91.3M | -0.9x | --- |
Hillevax Inc | 90.6M | -0.6x | --- |
Annovis Bio, Inc. is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and other chronic neurodegenerative diseases. The Company is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury (TBI) and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from six to three.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $93.7M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 13.8M |
Annovis Bio Inc does not pay a dividend. | |
Beta | 1.63 |
EPS | $-3.76 |
Book Value | $-0.74 |
P/E Ratio | -1.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.